Physician profile
Jorge Gomez
NPI 1568443356
$4,481.81
in general payments reported to CMS, 2019-2025
24 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $311 · 2021: $170 · 2022: $2,147 · 2023: $152 · 2024: $1,312 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228 · Travel and Lodging: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.78 |
| Travel and Lodging | $494.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,093.74 | 2022-2024 | |
| Pfizer INC. | $224.77 | 2020-2024 | |
| Elutia, INC. | $207.60 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.07 | 2021-2022 | |
| Lilly USA, LLC | $119.14 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Atricure, INC. | $107.28 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Exact Sciences Corporation | $100.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $66.30 | 2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $57.39 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $34.53 | 2020-2023 | Verquvo |
| Abbvie INC. | $32.68 | 2024 | |
| Astellas Pharma US INC | $29.81 | 2023 | Veozah |
| Janssen Pharmaceuticals, INC | $27.69 | 2025 | Spravato |
| Abbott Laboratories | $26.88 | 2023 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $24.53 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $20.32 | 2019 | |
| Cardiva Medical, INC. | $20.31 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Idorsia Pharmaceuticals US INC | $19.06 | 2023 | Quviviq |
| Smith+Nephew, INC. | $17.01 | 2022 | |
| Glaxosmithkline, LLC. | $16.50 | 2024 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $15.66 | 2024 | Eliquis |
| Abiomed | $13.95 | 2022 | |
| Tactile Systems Technology INC | $12.75 | 2020 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.